NCT03502330 - APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2018

Primary Completion Date

January 5, 2022

Study Completion Date

May 15, 2024

Conditions

Advanced MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma

Interventions

DRUG

APX005M

APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.

DRUG

Cabiralizumab

Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.

DRUG

Nivolumab

Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.

Trial Locations (1)

06510

Yale Cancer Center, New Haven